• Epizyme's Soft Tissue Cancer Drug Granted Speedy FDA Approval

    8 monthes ago - By Xconomy

    Epizyme won accelerated FDA approval Thursday for a drug developed to treat the rare cancer epithelioid sarcoma. The regulatory decision for the Epizyme drug, tazemetostat , covers patients 16 or older whose ES has advanced or spread and is not eligible for surgical treatment. The drug is now the first FDA-approved treatment for this type of cancer, laying the groundwork for potential applications of the therapy in other cancers. Cambridge, MA-based Epizyme set a $15,500 per month wholesale price for tazemetostat, before any discounts or rebates. The company aims to make the drug available...
    Read more ...